Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by D.M. Ponomarenko
Clinical Experience of Dual Targeted Blockade (Pertuzumab + Trastuzumab + Docetaxel) in Neoadjuvant Therapy of Early HER-2-Positive Breast Cancer
Effective Pharmacotherapy
Application of Anti-Pd-L1 Monoclonal Antibody Atezolizumab in Second Line Therapy of Common Urothelial Bladder Cancer
Effective Pharmacotherapy
Related publications
Pcn163 - Cost-Effectiveness of Add-On Pertuzumab Combined With Trastuzumab and Docetaxel Versus Placebo as Treatment of Her-2 Positive Metastatic Breast Cancer in Czech Republic
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn74 - A Budget-Impact Analysis of Adjuvant Pertuzumab and Trastuzumab in Early Her2-Positive Breast Cancer
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Safety Assessment of Neoadjuvant Pertuzumab Combined With Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia
International Journal of Breast Cancer
Cancer Research
Oncology
Pharmacology
A Randomized, Controlled Phase II Trial of Neoadjuvant Ado-Trastuzumab Emtansine, Lapatinib, and Nab-Paclitaxel Versus Trastuzumab, Pertuzumab, and Paclitaxel in HER2-positive Breast Cancer (TEAL Study)
Breast Cancer Research
Cancer Research
Oncology
Comparison of the Efficacy and Survival Analysis of Neoadjuvant Chemotherapy for Her-2-Positive Breast Cancer
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
Neoadjuvant Chemotherapy With Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results After a Median Follow-Up of Over 4 Years
Breast Care
Surgery
Oncology
HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Trastuzumab in Combination With Metronomic Cyclophosphamide and Methotrexate in Patients With HER-2 Positive Metastatic Breast Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
Patient With Metastatic Breast Cancer, HER2-positive, Trastuzumab- And Pertuzumab-Resistant Responding to Lapatinib
AboutOpen
